[JTPA-list] KEIZAI SOCIETY U.S.：グローバル・バイオテック産業 将来の見通し

[jtpa-list ＠ jtpa.org]

他団体イベントのお知らせです。

************************************************************
KEIZAI SOCIETY U.S. - JAPAN BUSINESS FORUM
************************************************************

グローバル・バイオテック産業 将来の見通し

パネリスト:
Dr. Roger Wyse
Managing Director and General Partner, Burrill & Company
A member of Int’l Advisory Panel for Biotechnology for Malaysia’s Prime Minister

Dr. Mary Haak-Frendscho
President and CSO, Takeda San Francisco

Dr. Akiko Futamura
President and CEO, InifiteBio

Mr. Haru Morita
President and CEO, REGiMMUNE

2010年10月28日(木)
登録およびネットワーキング: 5:30 ? 6:00 p.m.
イベント: 6:00 ? 8:00 p.m.
Wilson Sonsini Goodrich & Rosati (WSGR)
650 Page Mill Road, Palo Alto, CA 94304

軽食とソフトドリンク

料金:
10/24 11:00pm までに登録の方： $20
10/27 5:00pm までに登録の方：$35
当日参加の方：$50
(当日参加は歓迎しますが、席に限りがあります。)
服装: ビジネスカジュアル
経済ソサエティのウェブサイトで登録してください。www.keizai.org

Ustreamによるインターネットライブ放送
料金：無料。10/26 5:00pm（日本時間 10/27 9:00am）までに登録してください。
ご登録いただいた方には、インターネット放送の詳細を 10/27にお送りいたします。
イベントの概略

サンフランシスコ・ベイエリアはバイオテクノロジーの革命発祥の地です。今回の
フォーラムでは、バイオテック産業の将来の展望を探るべく、パネリストらが以下の
問題について討議します：経済危機とその余波の影響を受けバイオテック産業におけ
る事業形態がいかに変化したか？新興マーケットが既存マーケットに与える影響は？
注目すべき国境を越えた取引とは？今日のグローバル経済で成功する秘訣は？注目に
値する優れたイニシアチブをとっている地方政府は？そのイニチアチブから学ぶべき
ことは何か？

パネルディスカッションの冒頭でAkiko Futamura氏にグローバル化された今日の
バイオテック産業の概要を説明していただきます。バイオテック企業はどのような
問題・課題に直面し、生き残りと成功をかけ、いかなる努力を行っているのでしょうか。

Roger Wyse 氏 には、増加し続ける食糧とエネルギーに対する需要をバイオテクノロジーの
利用によりいかに満たすことができるかについて話していただきます。人口が急速に
増加する中、この需要を満たすことは、地政学的な観点からも、経済的な観点からも、
21世紀の最も重要な問題であり、多くの議論を呼んでいます。産業アプリケーション、
世界の食糧安全保障、そして持続可能性はバイオテック産業でいかに展開されているの
でしょうか。Dr. Wyse は顧問という立場で地方政府へのアドバイスを行い、幅広い
投資経験を有しています。プライベートセクターと共に増加し続ける食糧・エネルギー
に対する需要を満たすばかりでなく、さらに一歩踏み出て業界のリーダーになろう
というイニチアチブが政府組織に存在するなど、我々の政府組織に関する見方を一新
するような議論をお楽しみください。

Dr. Mary Haak-Frendschoには、企業の観点から、世界的な経済危機を乗り越え将来的な
成長をかけて大手バイオテック企業やバイオ医薬品メーカーが取っている事業戦略に
ついて話していただきます。R&D の展望を踏まえ、米国がバイオテック産業のR&D と
製造において世界のリーダーであり続けているのかどうかを検討します。イノベーションと
マネージメントがいかに国境を越えて実践され、企業の生き残りを左右しているのでしょうか？

Haru Morita 氏にはその奥深い経験に基づき、産業が不況から回復する中でスタート
アップ会社が直面するであろうリスクあるいは事業チャンスについて話していただきます。
さらに、市場機会と規制プロセスの観点から、海外のスタートアップ会社が米国で事業を
行うにあたり享受できる利点を他国との比較で議論します。




経済ソサイエティの2010年のテーマは「Catch the Next Wave ? New Opportunities for
2010」です。このフォーラムは、世界経済がどのように不況から回復し、次の波にのり、
そして、次々にやってくる新しいチャンスを掴むのかに焦点を当てて開催しています。
名刺をたくさんお持ちになり、イベントの参加者と名刺を交換してください。
苦境の時期は、ネットワークや助け合いが重要です。Next Waveの力を拡散するために、
このメールを知り合いの方に転送してください。


Dr. Roger Wyse is a Managing Director and General Partner at Burrill & Company,
a leading Life Sciences company with $1 billion in venture capital
under management,
with businesses in merchant banking, private equity and media.  Dr. Wyse joined
Burrill in 1998 and has led the development of Burrill & Company’s agriculture,
nutraceuticals, health & wellness, and industrial biotechnology
related activities
in venture capital investing. In this endeavor he pioneered the
“Virtual Corporate Venture”
model and has attracted over 40 corporate investors into the various
Burrill funds.
Dr Wyse chairs or serves on the boards of 11 private companies.  He is
Co-Chairman of
the $150M Malaysian Life Capital Fund and is a member of the
International Advisory
Panel for Biotechnology (BioIAP) for the Prime Minister of Malaysia.
He was founder
and Chairman of the Alliance for Animal Genome Research. He serves on
the Board of
Industrial Section of BIO. Dr. Wyse is a sought after speaker on biotechnology
applications and policy in food, agricultural and
bio-clean-technology. He has over
30 years of experience as an internationally recognized scientist and
as a Dean at
two major research universities; Rutgers and the University of
Wisconsin-Madison.
Immediately prior to joining Burrill & Company, Dr. Wyse served for 5
years as Dean
of the College of Agricultural and Life Sciences at the University of
Wisconsin-Madison.

>From 1986 ? 1992, he served as Dean of Research at Rutgers University.

In research,
Dr. Wyse earned international recognition for his basic studies in
plant biochemistry.
He published over 150 scientific papers. In recognition of his
research accomplishments
he received the prestigious Arthur Flemming Award in 1982 as the
Outstanding Young
Scientist in the US Federal Service. He was elected a Fellow of the
American Association
for the Advancement of Science, the Crop Science Society of America
and The American
Society of Agronomy. He also served as a consultant to numerous
Fortune 500 companies.


Dr. Mary Haak-Frendscho is President and Chief Scientific Officer of
Takeda San Francisco.
She established Takeda's new center of excellence for biologics, which
also serves as the
therapeutic antibody (Ab) IND engine for Takeda Pharmaceutical
Company, Japan’s largest
biopharmaceutical and biotech company. Dr. Haak-Frendscho leads the
overall Ab target
discovery, Ab drug discovery, and preclinical development activities
for oncology,
inflammatory and metabolic candidate medicines. In addition, she is
responsible for
actively expanding Takeda's US science, business, and intellectual
property presence
in the Biotech sector. Dr. Haak- Frendscho has nearly 20 years of
industry experience
at companies including Genentech, Abgenix and XOMA. She is an inventor
on over 25 issued
and pending patents, authored about 70 scientific articles, and has an
adjunct appointment
at the University of Wisconsin where she obtained her PhD.


Dr. Akiko Futamura is President and CEO of InfiniteBio. Formerly, she
was Executive Vice
President, Science and Technology/Business Development at SC
BioScience USA, a subsidiary of
Sumitomo Corporation, and Vice President, Science and Technology at
Summit Biotech,
a venture capital arm of Sumitomo Corporation. She was responsible for
identifying key
technologies, conducting due diligence and was involved in business
development at
therapeutics and platform (tool) companies. She played a key role in
concluding a number of
important alliances and investments with companies such as Morphotek,
Cyntellect,
QuantumDot Corporation, Xenogen, Panomics and Multispan. At
InfiniteBio, Dr. Futamura
has assisted numerous Japanese companies commercialize novel in vitro
and in vivo technologies
in the U.S., including PhoenixBio, SCIVAX Corporation, and ReproCELL.
Dr. Futamura received
her BS in biotechnology from the University of Tokyo, and Ph.D. in
biochemistry from the
University of Illinois. She is currently serving as a visiting
professor at Osaka University,
Japan, and is working to transfer novel technologies from Japan to the
U.S.  Dr. Futamura
is a co-founder of the Japanese Scientists Network in the U.S.


Mr. Haru Morita has served as President, CEO and Director of
REGiMMUNE, which is headquartered
in Japan but has a US subsidiary in Mountain View, California. Mr.
Morita has been with
REGiMMUNE since founding it in 2006 and has raised over US$20 million
two years ago.
Prior to REGiMMUNE, Mr. Morita served on the management teams of Y's
Therapeutics, Ltd.
and Y's Therapeutics, Inc., most recently as Director of Business
Development with
responsibility for corporate planning as well. Mr. Morita's
professional experience also
includes management consulting at Booz Allen and Hamilton (Tokyo
office). In this capacity
as consultant, he helped clients to establish and implement strategy
not only in pharmaceutical
business but also in other area such as chemical and consumer
products.  Prior to that,
Mr. Morita worked as a research scientist in the medical research
division of Kirin Brewery
Co. Ltd (lately it merged into Kyowa-Hakko-Kirin). At Kirin he was
part of the research and
development team that was first to clone Megakaryocyte Growth and
Differentiation Factor
(MDGF or Thrombopoietin). Mr. Morita received both of his BS in
Chemical Engineering and MS
in Molecular and Cellular Biology from the University of Tokyo.




Keizai Society wishes to thank its sponsors:

Intrax Cultural Exchange
Tazan International
Fenwick & West
Wilson Sonsini Goodrich & Rosati
USAsia Venture Partners
ZL Technologies
SunBridge
Union Bank